The company has developed a dried blood spot sampling method that collects precise volumes of blood, enabling quantification of samples.
Capitainer hopes to change dried blood spot sampling with its proprietary qDBS (quantitative dried blood spot) sampling kit, which allows patients to produce quantifiable blood samples from the comfort of their own home.
DBS is an antiquated medical technology discovered in the 1910s, and first used widely in the 1960s. A patient pricks...
Create an account to read this article
Already a subscriber?
Arima Genomics launched its new Aventa Lymphoma test aimed at helping pathologists detect lymphomas missed by standard FISH analysis. Initially positioned as complementary technology, Arima hopes to become the new standard test.
Salient's inflammatory bowel disease test, built on the start-up’s Signal platform, is planned to launch in March 2026. The company leverages rich data from existing wellness tests to develop signatures, focusing on conditions that are often misdiagnosed and disproportionately affect women.
The UK government expects that its new nation-wide network will enable companies to set up clinical trials more quickly and expand access to diverse patient populations across the National Health Service.
A recent conference panel discussed the stagnation in diagnostics regulation, highlighting the FDA's failed regulatory efforts on lab-developed tests. Political and legislative challenges hinder other reforms, and concerns over Medicare reimbursement cuts loom for the clinical lab industry.
Roche’s scanners have been integrated with PathAI’s AISight Dx system. The system’s FDA-cleared PCCP allows new components to be validated and integrated without additional FDA clearance. Eric Walk, chief medical officer, hints at future biopharma companion diagnostic collaborations.
Salient's inflammatory bowel disease test, built on the start-up’s Signal platform, is planned to launch in March 2026. The company leverages rich data from existing wellness tests to develop signatures, focusing on conditions that are often misdiagnosed and disproportionately affect women.
The UK government expects that its new nation-wide network will enable companies to set up clinical trials more quickly and expand access to diverse patient populations across the National Health Service.
